TGL WHAAAAAAAT! Alerts, thoughts, discussion. Message Board

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Microcap & Penny Stocks : TGL WHAAAAAAAT! Alerts, thoughts, discussion.

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next

To: StockDung who wrote (131983)	4/27/2004 3:23:19 PM
From: StocksDATsoar	Read Replies (1) of 150070

HEY TS, WTF IS African sleeping sickness (Trypanosomiasis)LMAOANDBALLS COMTEX) B: IMM: FDA Grants Fast Track Designation for DB289 [delayed] ( E B: IMM: FDA Grants Fast Track Designation for DB289 [delayed] ( EventX/Knobias.c Ridgeland, MS, APR 26, 2004 (EventX/Knobias.com via COMTEX) -- Immtech International Inc (AMEX: IMM) announced that the FDA has granted Immtech's first oral drug, DB289, fast track drug development designation for use to treat human African sleeping sickness (Trypanosomiasis). The FDA's fast track designation is recognition that DB 289 potentially represents an important new drug to combat and treat this life-threatening disease for which no other oral treatment exists. Most importantly, studies have demonstrated DB 289's effectiveness to treat human African sleeping sickness without the serious side effects associated with alternative (non-orally deliverable) drugs. Fast track designation also allows DB 289 to be eligible for expedited FDA review. GET KNOBIAS IN REAL-TIME: Delivery of this proprietary Knobias alert has been delayed by at least 10 minutes. To get all Knobias alerts in real-time daily, visit knobias.com ABOUT KNOBIAS: Knobias is a premier financial information provider of trading and investing data covering all U.S. equities for investors and security professionals. Knobias is best described by its three major components: Real-time desktop applications providing quotes, charts, level 2, analysis etc.; Knobias RAiDAR providing thousands of real-time news stories, alerts and documents daily; Knobias fundamentals providing a comprehensive database of fundamental research information. CONTACT: Knobias.com, LLC 601-978-3399 601-978-3675 info@knobias.com www.knobias.com/cmtx Copyright 2004 Knobias.com, LLC, All rights reserved. -0- SUBJECT CODE: Important Co. News Mover FDA/R&D KNO-Zone

Report TOU Violation

Share This Post

Public Reply Prvt Reply Mark as Last Read File

Previous 10 Next 10 Previous Next